Euclid Techlabs and collaborators at the Argonne Wakefield Accelerator (AWA) have received an Accelerator R&D and Production (ARDAP) award to continue the development and testing of a high dose rate electronic brachytherapy device. Partnering with Northwestern Proton Center, Euclid has designed and built a fully automated device intended to deliver dose rates exceeding 1 Gray per minute for treatment of both external and internal types of cancer. This device is intended to replace the commonly used iridium-192 radiation sources, which pose both a security and health risk to medical staff and patients.
The team will demonstrate and test the full functionality of the electronic brachytherapy system at the AWA facilities. This is an important step in bringing Euclid’s device closer to clinical trials and future product launch in the marketplace.